FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:2078-2079 June 27, 2002 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Marchbanks, P. A. PubMed Citation

The development of oral contraceptives stands as a major advance in women's health in the past century. By virtue of their ability to prevent pregnancy in 99 percent of women who use them properly, oral contraceptives have revolutionized reproductive choices for women. But concern about possible adverse effects persists — especially concern about breast cancer, because of laboratory and epidemiologic evidence linking steroid hormone exposure to breast cancer.¹

The Cancer and Steroid Hormone (CASH) study, a landmark case–control study reported in the Journal in 1986, did not show any association between oral-contraceptive use and breast cancer (relative risk, 1.0; 95 . . . [Full Text of this Article]

This article has been cited by other articles:

• Blander, C. L., Yager, J. D., Davidson, N. E. (2006). Estrogens and Breast Cancer. NEJM 354: 1647-1648 [Full Text]  
• Lippman, S. M., Hong, W. K. (2002). Cancer Prevention Science and Practice. Cancer Res. 62: 5119-5125 [Full Text]  
• (2002). OCs Do Not Increase Risk for Breast Cancer. JWatch General 2002: 1-1 [Full Text]